Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies
Reason given: lack of recruitment
Key facts
- Where
- Bordeaux, Caen, Dijon, Marseille, Montpellier, Paris, Saint-Herblain, and Toulouse, FranceSee the 9 sites
- Phase
- Phase 4
Where in France
- Institut BergonieBordeaux, FranceNo longer taking part
- Centre François BaclesseCaen, FranceNo longer taking part
- Centre Georges François LeclercDijon, FranceNo longer taking part
- Assistance Publique Des Hopitaux de MarseilleMarseille, FranceNo longer taking part
- Institut Paoli-CalmettesMarseille, FranceNo longer taking part
- Institut du Cancer de MontpellierMontpellier, FranceNo longer taking part
- Institut CurieParis, FranceNo longer taking part
- Institut de Cancérologie de l'OuestSaint-Herblain, FranceNo longer taking part
- IUCT-Oncopole Institut Claudius RigaudToulouse, FranceNo longer taking part
Trial details
- Who runs it
- Institut Paoli-Calmettes
- Trial code
- NCT03673332
- Record updated
- 22 January 2026
- Original description
The co-primary objectives will be to assess the safety and quality of life under treatment.Read full original descriptionShow less
Elderly Cancer PatIents Treated for Advanced or Metastatic Melanoma or NSCLC, Safety and qualiTy of Life Under immunOtheraPies: a Phase IV Trial
The co-primary objectives will be to assess the safety and quality of life under treatment.
Inclusion: Patients eligible to start a treatment including immune checkpoint inhibitors (Nivolumab, Ipilimumab, Pembrolizumab, and so on…); Diagnosis of advanced or metastatic melanoma or NSCLC (All treatment lines will be allowed); Age ≥ 70 years; Having personally signed and dated informed consent; Patient affiliated to the ''National security'' regimen or beneficiary of this regimen.
Exclusion: Immune checkpoint inhibitor therapy initiated before study enrolment; Concomitant participation in other investigational clinical trials involving an immune checkpoint inhibitor; Immune checkpoint inhibitor treatment in a context of other solid tumours; Immune checkpoint inhibitor treatment in a context of haematological malignancies; Being unable or unwilling to comply with the requirements of the protocol, as assessed by the investigator; Patient in urgency situation, adult under legal protection, or unable to give his consent.